A nested polymerase chain reaction (PCR) assay was investigated for detection of Pneumocystis carinii in 96 respiratory tract specimens from 82 children, of whom 28 were immunocompetent but with chronic lung disorders (CLD), eight had AIDS and R carinii pneumonia (PCP), 16 had AIDS but no respiratory symptoms, and 30 were healthy immunocompetent children. Gomori methenamine silver stain (GMS) and indirect immunofluorescence assay (IFA) were performed in parallel. Of 36 specimens from children with CLD, 12 were R carinii PCR-positive compared to 10 positive by GMS-IFA. Of eight specimens from children with AIDS and PCP, seven were R cariniipositive by PCR and six by GMS-IFA, and of 22 specimens from HIV-positive children without respiratory symptoms, two were positive by PCR and none by GMS-IFA. R carinii DNA was also detected by PCR in blood samples from four children with R carinii-positive nasopharyngeal aspirates. Specimens from healthy children were negative for I? carinii by both PCR and GMS-IFA. Of the seven children with CLD, who were R carinii-positive, two had clinical and microbiological improvement with co-trimoxazole treatment, two improved initially but relapsed, and one had R carinii cysts persistently in follow-up specimens despite co-trimoxazole treatment. These results suggest an association between R carinii and exacerbations of CLD in childhood, in the absence of HIV infection or other immunodeficiency syndromes.
Introduction
In immunocompromised patients, and particularly in those with AIDS, Pneumocystis carinii pneumonia (PCP) is one of the most frequent opportunist infections. It may result from a pneumocystis infection de novo or from reactivation of latent childhood infection.
Reports of PCP in non-immunocompromised patients are rare and appeared before testing for HIV and the detailed assessment of immune function were available [I] . DNA amplification studies have failed to detect P carinii in sputum or autopsy lung tissue from immunocompetent patients [2, 31, or This study evaluated the presence of 19 carinii in respiratory specimens from immunocompetent children with chronic lung diseases (CLD). I? carinii detection was investigated by conventional stains and by a nested polymerase chain reaction (PCR) assay with rat-derived P carinii oligonucleotides known to show significant homology with P carinii found in man. In a previous study, these oligonucleotides proved to be efficient primers for amplification of P carinii DNA from both rats and human patients with PCP and did not amplify DNA from a range of other pathogens including fungi [9] .
Materials and methods

Clinical specimens and patients
A total of 96 respiratory specimens including nasopharyngeal aspirates (NPA) and induced sputum samples was assayed for 19 carinii. Clinical specimens and the study population consisted of: group 1, 36 specimens from 28 HIV-seronegative children (1 -14 years) according to the CDC criteria, with normal Band T-lymphocyte counts, T-cell subsets and total immunoglobulins, who presented with various respiratory disorders; group 2, eight specimens from eight HIV-positive children with PCP diagnosed on clinical and radiological findings of whom six were I? cariniipositive by staining (one patient had earlier Toxoplasma gondii encephalitis and was receiving anti-I? carinii specific treatment at the time of sampling); group 3, 22 specimens from 16 HIV-positive patients without respiratory symptoms or chest X-ray abnormalities, of whom 10 presented with a high degree of immunosuppression (CD4+ lymphocyte counts < 200/mm3) and were receiving specific prophylaxis against I? carinii at the time of specimen collection; group 4, 30 specimens from 30 healthy, afebrile infants without active pulmonary infection who were not receiving immunosuppressive drugs and were age-matched and sex-matched for group 1.
Patients with CLD (group 1) were recruited between Nov. 1992 and Jan. 1995 from the Paediatric Institution of Rome after approval of the local Ethics Committee. An NPA was collected at admission for all patients. Some patients were evaluated prospectively to establish clinical or microbiological response, or both, to treatment and required further specimens (n = 1-6). Induced sputum samples were also assayed from five patients. Informed consent to perform anti-HIV testing was obtained. Nine HIV-infected children (group 3) had further single specimens which were investigated retrospectively for I? carinii after discharge from hospital, usually coincident with disappearance of clinical symptoms.
Respiratory specimens were assayed for E! carinii by PCR, indirect immunofluorescence assay (IFA) and tinctorial Gomori methenamine staining (GMS). Samples were also screened for bacteria, fungi, mycoplasmas, Mycobacterium tuberculosis and respiratory syncitial virus. The presence of other viruses, such as cytomegalovirus, coronaviruses and rhinoviruses, was not investigated. Single or muliple blood samples were also obtained from each patient and the controls and these were tested by PCR.
Specimen processing
NPA specimens were collected on admission as described previously [lo] . NPA and induced sputa were liquefied with sputolysin (6.5 mM dithiothreitol; Unipath, Basingstoke) and then vortex mixed with glass beads for 3 min. An equal volume of phosphate-buffered saline (PBS, pH 7.2) was added and samples were centrifuged at 3000 rpm for 15 min. A portion of the pellet was resuspended in 1 ml of PBS and stored until required for PCR assay. A further portion was either smeared on IFA slides or stained by a rapid GMS [ 1 11.
Immunofluorescence antibody test (IFA)
Specimens were fixed in cold acetone for 10 min and then treated with trypsin (2.5 g/L) to remove proteins covering antigenic sites of the pathogen. Anti-I? carinii monoclonal antibodies (MAbs) (Monofluo kit Pneumocystis, Diagnostic Pasteur, Marnes La Coquette, France) prepared against human I? carinii cysts and specific for cyst-wall antigen were employed [ 121. An IFA specimen was considered positive if two or three good cysts were seen in at least three high power fields. Both the IFA and GMS preparations were examined blindly by different people.
Polymerase chain reaction procedure (PCR)
Approximately 1 ml of sample was centrifuged at 15 000 rpm for 3 min; pellets were resuspended in 400 pl of proteinase K buffer containing 500 pg of proteinase K (Boehringer Mannheim Biochemicals). After overnight incubation at 37"C, DNA was extracted by phenol-chloroform-isoamyl alchohol followed by ethanol precipitation. Two primer sets based on the chromosomal rRNA sequence of rat-derived I? carinii
were used in a nested PCR as described previously [9] . The amplification mix contained 10 mM Tris-HC1 (pH 8.3, supplemented with 50mM KCl), 200mM of each deoxynucleotide triphosphate, 0.25 m~ of each primer, AmpliTaq DNA Polymerase 25 U/ml, and 2.5 mM MgClz in a h a 1 reaction volume of 50 pl (all reagents from Perkin-Elmer, Nonvalk, USA). Samples were subjected to initial amplification with external primers (35 cycles of 1 min, 94°C; 1 min, 50°C; 2 min, 72°C) followed by re-amplification with inner primers (25 cycles). The DNA products of 378 bp for the external primers and 312 bp for the inner primers were detected by gel electrophoresis and staining with ethidium bromide. The PCR product (10-pl samples) was further analysed by Southern hybridisation with a radiolabelled oligonucleotide probe. Samples were declared positive if a band of appropriate size was detected by autoradiography.
For blood PCR, peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation (Lymphoprep, Nycomed) within 2 h of collection. DNA was extracted by the method of Kawasaki [ 131.
PBMCs were incubated overnight with proteinase K and DNA was extracted as above.
Precautions appropriate for the prevention of crosscontamination of PCR assays were strictly observed [14] . Each stage was performed in separate rooms, pipettes and bottles were regularly autoclaved and gloves were changed frequently. 
Controls
Results
Clinical and laboratory data are summarised in Tables  1 and 2 .
Group 1. Arnong the 28 immunocompetent children with CLD, asthma (n = 4) and chronic bronchitis (8) were the most frequent diagnoses. Other underlying conditions included immotile cilia syndrome (1) and middle lobe syndrome (2), atopy and respiratory allergy with recurrent episodes of bronchopneumonia (2) and bronchiolitis with otitis media (2). Principal symptoms leading to admission were productive cough for at least 3 months of a year according to published carinii cysts in follow-up specimens. Two children were treated with other antibiotics with no activity against P carinii, both improved initially but relapsed.
Group 2. Of the eight HIV-positive patients with probable PCP, two presented with productive or dry cough without dyspnoea, four had fever and dyspnoea, and two had dyspnoea only. Radiological signs varied from perihilar markings to bilateral interstitial shadowing. Five patients were hypoxaemic. In six patients, PCP had been confirmed previously by GMS. Of the eight specimens collected from these patients, seven (87.5%) were PCR-positive, including the six known GMS-positive specimens which were also confirmed as positive by IFA. The single PCR-positive, GMS-IFAnegative specimen was from the child receiving anti-PCP proplyaxis.
Group 3. The other 16 HIV-infected children had advanced AIDS but no pulmonary symptoms. In this group P carinii DNA was also detected in two (9%) specimens obtained from one patient.
Group 4. All 30 control children were negative for P carinii by PCR, GMS and IFA.
P carinii DNA was detected in four blood specimens: one from a CLD case with NPA samples positive for P carinii by both microscopy and PCR (case 1, Table  2) , two from HIV-infected patients with documented PCP and with NPA positive by both staining and PCR, and one from an HIV-infected patient with no respiratory symptoms but with an NPA positive by PCR only.
Discussion
In HIV-positive children and adults, PCP is the most common AIDS-defining diagnosis, occurring in 30-50% of all cases. In children, PCP has also been described in patients with predisposing conditions such as neoplasms, organ transplants, hypogammaglobulinaemia and immunosuppressive therapy [ 161. Subclinical P carinii infection has been recognised at autopsy in healthy immunocompetent children [ 171. Furthermore, specific antibodies have been shown to develop by the age of 4 years, indicating ubiquitous early exposure to the organism, [18, 191. The present study investigated the role of P carinii in immunocompetent children with CLD. P carinii was detected by PCR in 12 of 36 NPA specimens from children admitted with exacerbations of CLD; 10 of these were confirmed by IFA and GMS. In contrast, P carinii was not detected in NPA samples from 30 healthy children. However, the role of E! carinii in the respiratory disease of children with CLD was unclear. Cross-contamination between cases was unlikely, as bronchoscopes or other special equipment were not required to obtain NPA specimens. Several authors have suggested that P carinii may be a transmissible pathogen in both animals and man [20, 211. However, none of the children positive for PCP was known to have been exposed to patients with PCP. The isolation of co-pathogens in these patients is not surprising. Culture results of NPAs and other respiratory samples are often difficult to interpret because of the carriage of potential respiratory pathgens in the upper airways. Furthermore, clinical and radiological features were non-specific in many study patients some of whom were already receiving antimicrobial therapy, further complicating the clinical and microbiological picture.
Although the role of P carinii in exacerbations of CLD needs further clarification, the inflammatory reaction and bronchial obstruction seen in CLD might permit proliferation of P carinii in the lung.
Two CLD children with I? carinii improved with cotrimoxazole therapy, suggesting that P carinii may have been responsible for the worsening of their pulmonary disease. Four patients improved on cotrimoxazole but then relapsed clinically and one was found to have P carinii cysts in follow-up specimens. Among the eight HIV-positive children with established PCP, one had a negative PCR result. The failure of PCR to amplify DNA in this specimen was probably due to long-term anti-PCP treatment, but loss of DNA during storage or routine manipulation could not be ruled out.
One of the PCR-postive GMS-IFA-negative specimen was from an HIV-positive child, who had taken prophylaxis for PCP; this patient had received both co-trimoxazole and aerosolised pentamidine. PCP prophylaxis may contribute to under-detection of E! carinii by conventional staining methods by reducing the number of organisms present in the respiratory Further work is required to determine whether longterm carriage of 19 carinii alone or with accompanying co-pathogens contributes to exacerbations of CLD and whether appropriate prophylactic or therapeutic regimens should be considered in these patients.
